share_log

科华生物2023中报解读:营业收入增长显著,净利润承压,现金流量净额大幅下滑

Interpretation of Kehua Biotech's 2023 Interim Report: Revenue increased significantly, net profit was under pressure, and net cash flow declined sharply

businesstimes cn ·  08/17/2023 14:10

According to Kehua Biotech's 2023 interim report, revenue for the reporting period was 1,396,475,774.51 yuan, up 54.66% from 902,928,251.87 yuan in the same period last year. This shows that the company has achieved significant growth in terms of business.

However, net profit attributable to shareholders of listed companies for the reporting period was 21,128,073.92 yuan, down 54.50% from 46,430,948.61 yuan in the same period last year. Meanwhile, net profit attributable to shareholders of listed companies for the reporting period after deducting non-recurring profit and loss was 6,885,105.47 yuan, down 84.63% from 44,781,944.58 yuan in the same period last year. The decline in these two data indicates that the company's profitability was under some pressure during the reporting period.

In terms of cash flow, net cash flow from operating activities during the reporting period was -592,060,407.58 yuan, down 1,545.77% from 40,951,115.03 yuan in the same period last year. This indicates that the company's cash outflow from operating activities is greater than the cash inflow, possibly due to an increase in the company's expenses to expand the scale of operations or increase investment.

In terms of assets and liabilities, total assets at the end of the reporting period were $7,457,864,308.88, down 15.38% from $8,813,157,013.32 at the end of the previous year. Meanwhile, net assets attributable to shareholders of listed companies at the end of the reporting period were 4,546,506,357.22 yuan, down 5.57% from 4,814,922,149.78 yuan at the end of the previous year. The decline in these two data indicates that the size of the company's assets has shrunk during the reporting period.

In terms of earnings per share, the basic earnings per share for the reporting period were 0.0411 yuan/share, down 54.49% from 0.0903 yuan/share in the same period last year. Meanwhile, diluted earnings per share for the reporting period were 0.0411 yuan/share, down 62.70% from 0.1102 yuan/share in the same period last year. The decline in these two data indicates that the company's profitability per share declined during the reporting period.

In terms of return on net assets, the weighted average return on net assets for the reporting period was 0.44%, down 0.79 percentage points from 1.23% in the same period last year. This indicates that the company's ability to return on net assets declined during the reporting period.

Overall, Kehua Biotech's revenue increased significantly in the 2023 interim report, but the sharp decline in net profit and net cash flow indicates that the company's profitability and cash flow management are under certain pressure. In the future, the company needs to further improve profitability and cash flow management to achieve better operating results.

As a financial analyst, I think investors need to fully consider the company's profitability and cash flow management issues when considering investing in Kehua Biotech, and also pay attention to the company's revenue growth.

This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment